MedTrace Logo

Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies

NCT01590628 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2022-05-20

Study results available
· View outcomes & findings →

Summary

Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients with Hemoglobinopathies

Conditions

  • Sickle Cell Disease & Thalassemia

Interventions

DRUG

NiCord

NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells

Sponsors & Collaborators

  • Gamida Cell ltd

    lead INDUSTRY

Principal Investigators

  • Joanne Kurtzberg, MD · Duke University Medical Center, NC, USA

  • Joel Brochstein, MD · Steven & Alexandra Cohen Children's Medical Center, New York

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2018-09-30
Completion
2019-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01590628 on ClinicalTrials.gov